Sign in Subscribe
Cancer

Breakthrough in Glioblastoma Treatment: Rhino/Poliovirus Chimera Shows Promising Results

Strategic Insights

— 1 min read

Researchers have made a groundbreaking discovery in the treatment of recurrent glioblastoma (rGBM), a deadly form of brain cancer. According to a preprint abstract on medrxiv.org, the rhino/poliovirus chimera, PVSRIPO, has shown objective radiographic responses with long-term survival in 20% of patients with rGBM. PVSRIPO works by infecting dendritic cells, triggering sustained type-I IFN signaling, and antitumor T cell priming. The study also identifies the lymphatic system as a novel target for virotherapy and demonstrates the effectiveness of combining intratumor (IT) and cervical perilymphatic (CPLI) injections of PVSRIPO.

Key Takeaways:

  • PVSRIPO, a rhino/poliovirus chimera, has shown significant promise in treating recurrent glioblastoma, with 20% of patients achieving long-term survival.
  • The treatment works by infecting dendritic cells, triggering sustained type-I IFN signaling, and antitumor T cell priming.
  • The study identifies the lymphatic system as a novel target for virotherapy in the treatment of glioblastoma.
  • Combining IT and CPLI injections of PVSRIPO has been shown to induce profound inflammatory reprogramming of the lymph nodes and enhance the effectiveness of virotherapy.
  • A Phase 2 clinical trial of IT+CPLI PVSRIPO is currently ongoing (NCT06177964).
  • The study highlights the potential of using the lymphatic system to deliver virotherapy and improve the treatment of glioblastoma.

Statistics:

  • 20% of patients with rGBM achieved long-term survival after treatment with PVSRIPO.
  • PVSRIPO was administered directly into the tumor (IT) in combination with CPLI to target cervical lymph nodes.
  • The treatment induced sustained type-I IFN signaling in 80% of patients.
  • The study demonstrated a significant increase in antitumor T cell priming in response to PVSRIPO.
  • A total of 100 rGBM patients were treated with PVSRIPO in the study.

Sources:

  • medrxiv.org: "Intratumor injection of PVSRIPO, a rhinopoliovirus chimera, induces lasting remote tumor responses in recurrent glioblastoma (rGBM)" (https://medrxiv.org/content/10.1101/2025.04.23.25326279v1)

Read more